Skip to main content

Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy

Newswire.ca - Tue Dec 16, 2025

Issued on behalf of Avant Technologies Inc.

Equity InsiderNews Commentary

VANCOUVER, BC, Dec. 16, 2025 /CNW/ -- The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations capturing 67.5% market share as the industry transitions from boutique R&D operations to scalable bioprocessing infrastructure[1]. Gene and CAR-T therapy demand has driven CDMO partnerships to expand viral vector production and GMP-compliant facilities at unprecedented velocity, overcoming bottlenecks that previously constrained commercial access[2]. Five companies positioned at this manufacturing convergence point are attracting institutional attention: Avant Technologies, Inc. (OTCQB: AVAI), ProKidney Corp. (NASDAQ: PROK), Mesoblast Limited (NASDAQ: MESO), Lineage Cell Therapeutics, Inc. (NYSE-A: LCTX), and BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI).

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).